White Matter Integrity According to BDNF Genotype After Stroke
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03647787 |
Recruitment Status :
Completed
First Posted : August 27, 2018
Last Update Posted : September 19, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Stroke | Other: observational study |
Study Type : | Observational |
Actual Enrollment : | 58 participants |
Observational Model: | Case-Only |
Time Perspective: | Retrospective |
Official Title: | Changes of White Matter Integrity According to BDNF Genotype During Motor Recovery After Stroke |
Actual Study Start Date : | May 25, 2018 |
Actual Primary Completion Date : | April 5, 2019 |
Actual Study Completion Date : | April 5, 2019 |
- Other: observational study
This study is a longitudinal observational study
- Fractional anisotropy [ Time Frame: 2 weeks to 3 months after stroke onset ]changes of fractional anisotropy (FA) in the corticospinal tract (CST)
- Fractional anisotropy [ Time Frame: 2 weeks to 3 months after stroke onset ]changes of fractional anisotropy (FA) in the intrahemispheric corticocortical tract from the primary motor cortex to ventral premotor cortex (M1PMv)
- Fractional anisotropy [ Time Frame: 2 weeks to 3 months after stroke onset ]changes of fractional anisotropy (FA) in the corpus callosum (CC)
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- diagnosed with first-ever hemispheric ischemic infarction with damage to the supratentorial area confirmed by brain MRI within 2 weeks after stroke onset
Exclusion Criteria:
- any clinically significant or unstable medical disorder or neuropsychiatric comorbidity

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03647787
Korea, Republic of | |
Samsung Medical Center | |
Seoul, Gangnam-gu, Korea, Republic of, 06351 |
Responsible Party: | Samsung Medical Center |
ClinicalTrials.gov Identifier: | NCT03647787 |
Other Study ID Numbers: |
2018-04-146 |
First Posted: | August 27, 2018 Key Record Dates |
Last Update Posted: | September 19, 2019 |
Last Verified: | September 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |